Ocrelizumab experience in treatment-resistant warts associated with Fingolimod: A case report

Abstract

Fingolimod is a sphingosine 1-phosphate (S1P) analogue that has antagonistic effects on S1P receptors. It creates an immunosuppressive effect by decreasing the number of circulating lymphocytes by preventing the exit of lymphocytes from lymphoid tissues. The causal link between fingolimod treatment and warts has not yet been proven. Herein, we report a case of relapsing–remitting multiple sclerosis in which multiple warts developed on the right hand over the years after the initiation of fingolimod treatment and disappeared completely after discontinuation of treatment.

Conclusions: The temporal relationship between discontinuation of treatment and healing of lesions, as in our case, supports a possible causal role of fingolimod and new warts did not form while receiving ocrelizumab treatment.